Kevin Buckley, J.D.

Founder & Senior US Patent Attorney

kevin@torreypineslaw.com
main: +1 (858) 869-1250

Kevin Buckley is an accomplished international patent attorney and the founder of Torrey Pines Law Group. He has more than 20 years of experience as a Biopharma and Digital Health executive, lawyer, and biochemist studying immuno-oncology, RNA-derived antiviral therapeutics, and bioinformatics systems.

He has handled complex intellectual property, transactional and FDA regulatory matters in what is now the world’s largest international law firm (now known as Dentons), the largest US university, the first medical device company to obtain FDA clearance for AI-enabled breast cancer detection, and in a commercial-stage international biopharmaceutical company.

He created Torrey Pines Law Group to help his clients bring lifesaving, enduring, and commercially valuable technologies to market.

His clients include healthcare, life sciences, digital health, biotechnology, pharmaceutical, medical device, clinical and in vitro diagnostics, specialty chemical, artificial intelligence (AI), and convergence technology businesses. The "convergence" often includes Machine Learning (ML), Deep Learning (DL), Natural Language Processing (NLP), computer vision, neural networks, and complex algorithms.

He successfully implements pharmaceutical lifecycle management, product lifecycle management, and worldwide patent portfolio development strategies. In addition, he regularly conducts IP due diligence related to international in-licensing and out-licensing transactions inbound and outbound to Europe, China, Canada, South America, Mexico, Korea, and Japan. He also conducts due diligence related to investment funding, mergers, acquisitions, licenses, and Initial Public Offerings.

Kevin has also assisted with drafting and negotiating contracts related to distribution, supply, manufacturing, licensing, resale, collaboration, joint venture, clinical trial, product marketing, data use, safety, pharmacovigilance, right of reference, and myriad other agreements. He engages a trusted network of local and international tax, securities, corporate, regulatory, and litigation counsel when required.

Areas of focus include:

• Intellectual Property, transactional, and regulatory counseling
• International patent preparation and prosecution
• IP and commercial transactions
• Technology licensing
• Investment funding and due diligence
• Legal opinion drafting (Freedom-To-Operate (FTO), patentability, patent validity, patent infringement, Paragraph IV certification, safe harbor, etc.)
• Pharmaceutical Lifecycle Management
• Product Lifecycle Management
• Litigation avoidance
• Litigation support
• IP infringement litigation

Kevin has been an academic advisor to entrepreneurship centers at the University of Pennsylvania (Wharton, Law, and Medicine), Washington University in St. Louis, and UC San Diego. He was also an Adjunct Professor at Washington University School of Law where he taught a Biotechnology Law intersession course.

When he is not in the office, you can find Kevin hiking the California backcountry or supporting San Diego County's growing community of vineyards and wineries. What he loves most, however, is spending time outdoors -- every single day -- with his daughter, family and friends.

Kevin received a Bachelor of Science degree in Biochemistry/Chemistry from UC San Diego where he was an undergraduate Research Scholar. He then received a Juris Doctorate from the University of Pittsburgh School of Law where he was Editor-in-Chief of the Pittsburgh Journal of Technology Law and Policy.

Distinctions

Kevin has been selected by his peers for inclusion in:

• The Best Lawyers in America® - Biotechnology Law
• Philadelphia's Best Lawyers
• SuperLawyers Rising Star
• St. Louis Magazine Best Lawyers
• St. Louis Business Journal "Who's Who in Technology"
• St. Louis Business Journal "40 Under Forty"

Featured Publications & Presentations

• Anticipate Success, MedTech Gurus (May 12, 2021)
• What Place Does IP Strategy Have in Life Sciences and AI? Data Futurology (March 17, 2021)
• How to think about intellectual property as a medical device company, when to think about it, and how IP fits into the overall company strategy, Project Medtech (March 8, 2021)
• The Effects of AI on IP, Pharmaceutical Executive (March 4, 2021)
• High Court Mulls Taking Up Diagnostic Patent Eligibility Fight, Bloomberg Law (February 26, 2021)
• IP & Patent Protection At The Perilous Pace Of Biopharma, BioProcess Online (September 14, 2020)
• Protecting the Intellectual Property of Your Medical Device Technology, Greenlight Guru (July 22, 2020)
• Patent Strategy at the Intersection of Life Sciences and Artificial Intelligence, IP Watchdog (March 12, 2020)
• Patent Drafting at the Life Sciences & AI Interface, IP Watchdog (January 22, 2020)
• Affordable Prescriptions for Patients Act Would Allow FTC to Prosecute Pharma Patent Thickets, Product Hopping , IP Watchdog (May 20, 2019)
• Tax Reform Aims to Keep IP in the U.S., San Diego Business Journal (February 1, 2019)
• Legal, Financial and Tax Strategies for Start-Ups, Sanford Consortium for Regenerative Medicine, San Diego, CA (January 28, 2015)
• IP Strategy Informed by the Commercialization Process, Pennsylvania Bio Inaugural Knowledge Fair, Valley Forge, PA (June 8, 2011)
• Entrepreneurial Investing - Management 424/524, Washington University Olin Business School, St. Louis, MO (October 13, 2009 and March 2, 2010)
• Bringing Overseas Start-Ups Into the U.S., Inaugural Global Healthcare Investing Conference, Cleveland, OH (June 20, 2007)

Jurisdictions

Kevin is registered to practice before the U.S. Patent & Trademark Office, and is admitted to practice law in Pennsylvania and Missouri. He is also admitted to the Federal Circuit Court of Appeals.